Luca Malorni
Luca Malorni
Hospital of Prato
Email verificata su
Citata da
Citata da
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ...
Clinical cancer research 11 (13), 4741-4748, 2005
Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial
AD Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
Journal of the National Cancer Institute 106 (1), djt337, 2014
Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial
AD Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
Journal of the National Cancer Institute 106 (1), djt337, 2014
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
CJ Creighton, S Massarweh, S Huang, A Tsimelzon, SG Hilsenbeck, ...
Cancer research 68 (18), 7493-7501, 2008
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients
M Pestrin, F Salvianti, F Galardi, F De Luca, N Turner, L Malorni, ...
Molecular oncology 9 (4), 749-757, 2015
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136 (3), 795-804, 2012
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
CD Hart, I Migliaccio, L Malorni, C Guarducci, L Biganzoli, A Di Leo
Nature reviews Clinical oncology 12 (9), 541, 2015
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology
M De Laurentiis, G Cancello, L Zinno, E Montagna, L Malorni, A Esposito, ...
Annals of Oncology 16, iv7-iv13, 2005
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patientsá…
L Malorni, S Piazza, Y Ciani, C Guarducci, M Bonechi, C Biagioni, ...
Oncotarget 7 (42), 68012, 2016
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes
MD Castellone, AM Cirafici, G De Vita, V De Falco, L Malorni, G Tallini, ...
Oncogene 22 (2), 246-255, 2003
New approaches for improving outcomes in breast cancer in Europe
A Di Leo, G Curigliano, V DiÚras, L Malorni, C Sotiriou, C Swanton, ...
The Breast 24 (4), 321-330, 2015
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breastá…
L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D’Hollander, ...
Annals of Oncology 29 (8), 1748-1754, 2018
RAI (ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors
V De Falco, V Guarino, L Malorni, AM Cirafici, F Troglio, M Erreni, ...
Oncogene 24 (41), 6303-6313, 2005
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
I Migliaccio, L Malorni, CD Hart, C Guarducci, A Di Leo
BMC medicine 13 (1), 46, 2015
Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis
M Barba, L Yang, HJ SchŘnemann, F Sperati, S Grioni, S Stranges, ...
Journal of Experimental & Clinical Cancer Research 28 (1), 135, 2009
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance
L Malorni, M Giuliano, I Migliaccio, T Wang, CJ Creighton, M Lupien, X Fu, ...
Molecular Cancer Research 14 (5), 470-481, 2016
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
I Migliaccio, A Di Leo, L Malorni
Current opinion in oncology 26 (6), 568-575, 2014
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
I Migliaccio, MF Wu, C Gutierrez, L Malorni, SK Mohsin, DC Allred, ...
Breast cancer research and treatment 123 (3), 651-660, 2010
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
C Guarducci, M Bonechi, G Boccalini, M Benelli, E Risi, A Di Leo, ...
Breast Care 12 (5), 304-308, 2017
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?
N Turner, M Pestrin, F Galardi, F De Luca, L Malorni, A Di Leo
Cancers 6 (2), 684-707, 2014
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20